Medicamen Biotech dividend 2025

MEDICAMEQ

383.5

4.25 (-1.10%)
Last updated on 24 Dec, 2025 | 15:29 IST
alert_iconwatchlist_icon
BUYSELL

alert_iconThe current prices are delayed, login to your account for live prices

Medicamen Biotech Dividend Details

Record Date

26-Sep-2025

Dividends Date

26-Sep-2025

Ex Date

26-Sep-2025

Dividend Type

Equity Share

Dividend Per Share

10.00

The Medicamen Biotech has declared a Equity Share dividend of 10 per share. Investors should note the record date of 26-Sep-2025, and the ex-dividend date 26-Sep-2025 to confirm eligibility for the payout. This move underscores the company’s ongoing efforts to enhance shareholder value through regular dividend distributions.

Medicamen Biotech Dividend History

Record DateDividend Per ShareDividend TypeEx-Date
26-Sep-20250.10Equity Share26-Sep-2025
19-Sep-20250.10Equity Share19-Sep-2025
01-Jan-00010.10Equity Share19-Sep-2024
01-Jan-00010.10Equity Share18-Sep-2024

Upcoming Dividends by Indian Companies

View More
No Data Found

Medicamen Biotech Dividend FAQs

The latest dividend declared by Medicamen Biotech is of 0.1 per share for the financial year as announced on 26-Sep-2025.

Registered shareholders who own Medicamen Biotech’s shares on or before the record date of 26-Sep-2025 set by the company are eligible to receive the dividend. You will not be entitled to the payout if you purchase shares on or after the ex-dividend date of 26-Sep-2025.

You can expect to receive Medicamen Biotech’s dividend in your bank account linked to your Demat account within 25 to 45 business days after the record date of 26-Sep-2025. The record date is when Medicamen Biotech identifies eligible shareholders for the dividend payment.

The annual dividend paid by Medicamen Biotech varies according to its financial performance and dividend policy. Generally, companies in different sectors exhibit varying dividend yields. To determine Medicamen Biotech's specific annual dividend, it’s advisable to consult the company's official investor relations website or recent financial statements.